Pharmafile Logo

India

- PMLiVE

EMA and ECDC publish advice on fourth doses of mRNA COVID-19 vaccines

The regulators have concluded that there is not enough supporting evidence for an immediate fourth dose

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments

The deal is set to benefit to 95 low- and middle-income countries, pending authorisation or approval

- PMLiVE

FDA to review requirements for future booster shots for COVID-19

The meeting will be streamed live on the FDA’s YouTube channel and a webcast will be provided on the FDA website

- PMLiVE

Moderna applies to FDA for authorisation for second COVID-19 booster shot for all adults

The second booster shot would be for adults 18 years and over who have already had one authorised COVID-19 booster shot

- PMLiVE

MHRA grants approval for AstraZeneca’s Evusheld in the UK

It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK

- PMLiVE

Pandemic Antiviral Discovery initiative created by the Novo Nordisk Foundation, Open Philanthropy and the Gates Foundation

The initiative, backed with funding of up to $90m, will aid in the discovery and development of antiviral drug candidates

- PMLiVE

Pfizer highlights need for fourth dose of COVID-19 vaccine to FDA

While new study published in The Lancet shows COVID-19 mortality rate is almost three times higher than previously thought

- PMLiVE

Pfizer begins phase 2/3 study of oral COVID-19 treatment in paediatric patients

The phase 2/3 trial involves around 140 patients under the age of 18

- PMLiVE

Results from trial show Eli Lilly’s COVID-19 drug improves survival rates

The RECOVERY trial is the biggest study of COVID-19 treatments in the world, involving more than 47,000 participants in the UK

- PMLiVE

Verily Life Science signs new contract with Oncimmune for long COVID study

The project will analyse potential patterns of autoantibodies, which are associated with developing long COVID

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links